Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods – 09 July 2025

Overview

The Therapeutic Goods Act 1989 was enacted by the Commonwealth of Australia to regulate the provision of therapeutic goods, including medicines, medical devices, and other health-related products. This Act was introduced to ensure the safety, quality, and efficacy of therapeutic goods available in Australia. The Therapeutic Goods Administration (TGA), a branch of the Department of Health, Disability and Ageing, is responsible for administering the Act. The policy objective behind the Act is to protect public health by regulating the manufacture, supply, and advertising of therapeutic goods. Recently, the TGA published details regarding the revocation of several Licences to Manufacture Therapeutic Goods, including those held by Johnson & Johnson Pacific Pty Ltd, CSL Innovation Pty Ltd, Golden Health Pty Ltd, Hallas Trading Co Pty Ltd, Scientest Analytical Services Pty Ltd, Herbal Supplies Pty Ltd, and Little Green Pharma Ltd, all at the request of the manufacturers. These revocations underscore the TGA's commitment to maintaining high standards in the therapeutic goods industry.

Scope and Application

The Therapeutic Goods Act 1989 applies to persons and entities involved in the manufacture, supply, advertising, and importation of therapeutic goods within Australia. This includes companies, individuals, and other entities that are engaged in activities related to therapeutic goods, such as medical devices, prescription and over-the-counter medicines, and complementary medicines. The Act covers the entire Commonwealth of Australia, thereby establishing a uniform regulatory framework for therapeutic goods across state and territory borders. The scope of the Act is further extended through subordinate instruments, which provide detailed guidelines and specific requirements for compliance. Notably, the Act does not apply to therapeutic goods that are subject to specific exemptions, such as those listed in the Poisons Standard or certain classes of goods that are regulated under other legislation. Additionally, some therapeutic goods may be subject to additional controls or restrictions based on their classification and potential risks. The revocation of a manufacturer's licence, as evidenced in the gazette, demonstrates the enforcement capabilities of the Therapeutic Goods Administration in maintaining compliance with legislative standards.

Key Provisions

The Therapeutic Goods Act 1989, through its Section 41(1)(d), empowers the Secretary to revoke a licence for the manufacture of therapeutic goods, as demonstrated in the notice dated 09 July 2025. This particular notice involves the revocation of licences held by several entities, specifically JOHNSON & JOHNSON PACIFIC PTY LTD, CSL INNOVATION PTY LTD, GOLDEN HEALTH PTY LTD, HALLAS TRADING CO PTY LTD, SCIENTEST ANALYTICAL SERVICES PTY LTD, HERBAL SUPPLIES PTY LTD, and LITTLE GREEN PHARMA LTD. Each of these companies has had their respective licences revoked at their own request. This action follows the formal procedures outlined within the Act and is executed by the Delegate of the Secretary, Neville Baker, as indicated in the notice. The revocation of these licences imposes certain obligations and requirements on the parties involved. Primarily, these companies must cease all manufacturing activities that fall under the scope of their revoked licences. Additionally, they are required to comply with any transitional provisions or directives issued by the Therapeutic Goods Administration (TGA) to ensure a smooth cessation of operations. The companies must also notify the TGA and any relevant stakeholders about the revocation, and they may be required to return any documentation or materials related to their manufacturing activities. Failure to comply with the terms of the revocation or any associated directives can lead to serious consequences. Under the Therapeutic Goods Act 1989, breaches of manufacturing regulations can result in both civil and criminal penalties. The maximum penalties for such offences are significant, reflecting the importance of compliance with therapeutic goods manufacturing regulations. These penalties can include substantial fines and, in severe cases, imprisonment for directors or officers of the companies involved. It is imperative for the affected companies to adhere strictly to the requirements and timelines set forth in the revocation notice to avoid these adverse consequences.